| Literature DB >> 31581601 |
Balázs Decsi1, Réka Krammer2, Kristóf Hegedűs3, Ferenc Ender4,5, Benjámin Gyarmati6, András Szilágyi7, Róbert Tőtős8, Gabriel Katona9, Csaba Paizs10, György T Balogh11,12, László Poppe13,14,15, Diána Balogh-Weiser16,17.
Abstract
Biomimetic oxidation of drugs catalyzed by metalloporphyrins can be a novel and promising way for the effective and sustainable synthesis of drug metabolites. The immobilization of 5,10,15,20-tetrakis(2,3,4,5,6-pentafluorophenyl)iron(II) porphyrin (FeTPFP) and 5,10,15,20-tetrakis-(4-sulfonatophenyl)iron(II) porphyrin (FeTSPP) via stable covalent or rapid ionic binding on aminopropyl-functionalized magnetic nanoparticles (MNPs-NH2) were developed. These immobilized catalysts could be efficiently applied for the synthesis of new pharmaceutically active derivatives and liver related phase I oxidative major metabolite of an antiarrhythmic drug, amiodarone integrated in a continuous-flow magnetic chip reactor (Magnechip).Entities:
Keywords: biomimetic oxidation; drug metabolism; liver-on-a-chip; microfluidics; organ-on-a-chip
Year: 2019 PMID: 31581601 PMCID: PMC6843572 DOI: 10.3390/mi10100668
Source DB: PubMed Journal: Micromachines (Basel) ISSN: 2072-666X Impact factor: 2.891
Figure 1Biomimetic oxidation of amiodarone catalyzed by metalloporphyrines immobilized on magnetic nanoparticles in continuous-flow magnetic chip reactor.
Figure 2Cross-sectional view of Magneflow chip holder with the microreactor chip. A layer of magnetic nanoparticles (MNP) is formed in the reaction chambers due to the magnetic field applied by moving the permanent magnets toward the microreactor chip. Layer consistency is assessed through the camera image; reactor temperature is maintained by the thermostat heat exchanger.
Dynamic light scattering (DLS) and ζ-potential data of the modified MNPs.
| Type of MNPs | ζ-Potential (mV) | |
|---|---|---|
| MNPs-NH2 | 429 ± 46 | −22.9 ± 0.8 |
| MNPs-NH-FeTPFP | 336 ± 25 | −16.0 ± 0.8 |
| MNPs-NH3-FeTSPP | 296 ± 4 | −5.3 ± 1.2 |
Figure 3Amiodarone (1) and the detected derivatives (the assumed structures were based on their HRMS signal) of amiodarone (2–14).
Metabolite profile of amiodarone from homogenous (free metalloporphyrin catalyzed: FeTPFP or FeTSPP) and heterogeneous (immobilized metalloporphyrin on MNPs: MNPs-NH-FeTPFP or MNPs-NH3-TSPP) biomimetic oxidations in batch mode.
| Metabolite a | In Vitro | Homogenous Biomimetic Reaction | Heterogeneous Biomimetic Reaction | ||
|---|---|---|---|---|---|
| FeTPFP | FeTSPP | MNPs-NH-FeTPFP | MNPs-NH3-FeTSPP | ||
| amiodarone ( | 86.4 | 8.1 | 4.3 | 6.3 | 53.0 |
| ( | 13.3 | 66.7 | 66.5 | 62.6 | 38.0 |
| ( | - | - | 1.0 | - | - |
| ( | - | - | 7.6 | - | - |
| ( | - | - | 10.5 | 1.4 | 1.4 |
| ( | - | 24.3 | - | 25.7 | 5.9 |
| ( | - | 0.9 | - | - | - |
| ( | - | - | - | - | 1.3 |
| ( | - | - | - | - | 0.4 |
| ( | - | - | - | - | 0.1 |
| ( | - | - | - | - | - |
| ( | 0.3 | - | - | - | - |
| ( | - | - | - | - | - |
| ( | - | - | - | - | - |
| other b | - | - | 10.0 | 4.0 | - |
a the structure and the amount of metabolites were determined by LC-MS measurement, where the ratio of metabolites based relative peak area (%) at λ = 220 ± 4 nm on DAD-chromatograms, b not identified compounds under limit of detection.
Biocatalytic activity (UB) and specific biocatalytic activity (UP) of human liver microsomes (HLM) and metalloporphyrins (FeTPFP or FeTSPP) in their soluble (homogenous catalytic reaction) and MNP immobilized (heterogeneous catalytic reaction) forms in biomimetic oxidation of amiodarone (1).
| Activity | Homogenous Catalytic Reaction | Heterogenous Catalytic Reaction | |||
|---|---|---|---|---|---|
| HLM | FeTPFP | FeTSPP | MNPs-NH-FeTPFP | MNPs-NH3-FeTSPP | |
| 0.5 | 132.7 | 153.6 | 12.1 | 6.1 | |
| - | 132.7 | 153.6 | 223.8 | 80.8 | |
Metabolite profile of amiodarone from immobilized metalloporphyrin (MNPs-NH-FeTPFP or MNPs-NH3-TSPP) catalyzed biomimetic oxidation in continuous-flow magnechip reactor–“Liver-on-a-Chip”.
| Metabolites a | Flow Rate (μL/min) | |||||||
|---|---|---|---|---|---|---|---|---|
| 15 | 30 | 45 | 60 | |||||
| FeTPFP | FeTSPP | FeTPFP | FeTSPP | FeTPFP | FeTSPP | FeTPFP | FeTSPP | |
| amiodarone ( | 61.0 | 58.8 | 75.7 | 77.0 | 84.5 | 84.4 | 88.4 | 87.9 |
| ( | 0.5 | - | 0.5 | 0.3 | 0.6 | 0.4 | 0.8 | 0.6 |
| ( | 10.8 | 11.5 | 5.6 | 5.6 | 2.7 | 2.7 | 1.1 | 2.2 |
| ( | 21.5 | 23.2 | 13.4 | 12.9 | 8.2 | 8.5 | 6.3 | 6.9 |
| ( | 3.9 | 4.4 | 3.3 | 3.0 | 2.6 | 2.9 | 2.3 | 1.8 |
| other b | 2.3 | 2.2 | 1.5 | 1.4 | 1.3 | 1.2 | 1.2 | 0.7 |
a the structure and the amount of metabolites were determined by LC-MS measurement, where the ratio of metabolites based relative peak area (%) at λ = 220 ± 4 nm on DAD-chromatograms, b not identified compounds under limit of detection.
Figure 4Turnover frequency (TOF) (a) and space time yield (STY) (b) values of metalloporphyrin (FeTPFP or FeTSPP) catalysts in their soluble (homogenous) or MNP-immobilized (heterogeneous) forms in biomimetic oxidation of amiodarone (1) in batch mode or continuous-flow magnetic chip reactor.